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Staphylococcus aureus is a prominent cause of human infections globally. The high prevalence of infec-
tions is compounded by antibiotic resistance—a signiﬁcant problem for treatment. Methicillin-resistant
S. aureus (MRSA) is endemic in hospitals and healthcare facilities worldwide, and is an increasingly com-
mon cause of community-associated bacterial infections in industrialized countries. Although much focus
is placed on the role of S. aureus as a human pathogen, it is in fact a human commensal organism that has
had a relatively long coexistence with the human host. Many S. aureus infections can be explained by host
susceptibility or other predisposing risk factors. On the other hand, the emergence/re-emergence of suc-
cessful S. aureus clones (referred to as epidemic waves) suggests a rapid bacterial adaption and evolution,
which includes the emergence of antibiotic resistance and increased virulence and/or transmissibility. It
is within this context that we review our understanding of selected S. aureus epidemic waves, and high-
light the use of genome sequencing as a means to better understand the evolution of each lineage.
 2013 Elsevier B.V.. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Staphylococcus aureus is a remarkably successful pathogen. De-
spite the availability of effective antimicrobial agents to treat S.
aureus infections, it continues to be a major cause of morbidity
and mortality worldwide (Lowy, 1998). Epidemics due to the
spread of successful clones continue to be reported from virtually
every geographic region (Chambers and DeLeo, 2009). As a result,
S. aureus has proven to be among the most persistent of pathogens
in the healthcare and community setting. In both venues the emer-
gence of antimicrobial resistant strains, especially those that are
resistant to methicillin, has been a constant feature. Many factors
appear to contribute to the success of S. aureus as a pathogen, how-
ever its capacity to persist as a commensal, its frequent resistance
to multiple antimicrobial agents and its armamentarium of viru-
lence determinants, often with redundant functions, are among
the most important (Fluit et al., 2001; Foster, 2005; Otto, 2010).
Methicillin-resistant S. aureus (MRSA) are well established in
both the healthcare setting and in the community. They are among
the most common causes of such nosocomial infections as intrave-nous catheter associated infections, ventilator associated pneumo-
nias and surgical wound infections in some industrialized
countries such as the United States (Klevens et al., 2006; Rosenthal
et al., 2012). More recently nosocomial infective endocarditis due
to MRSA has become a major concern (Benito et al., 2009). In the
community, MRSA are the most common cause of skin and soft tis-
sue infections in the United States (US). Five to ten percent of com-
munity-based infections are invasive and potentially life
threatening (Fridkin et al., 2005; Klevens et al., 2007; Moran
et al., 2006). The emergence of community-associated methicil-
lin-resistant S. aureus (CA-MRSA) as an important pathogen has oc-
curred over the past 15–20 years (Chambers, 2001; David and
Daum, 2010; DeLeo et al., 2010). In the United States, a single epi-
demic clone—USA300, emerged as the predominant isolate
accounting for the vast majority of cutaneous infections. These
community-based strains appear to have enhanced virulence as
well as an enhanced capacity to colonize multiple body sites and
to survive on environmental surfaces (DeLeo et al., 2010; Otto,
2010; Uhlemann et al., 2011). As a result they are also more easily
spread from person to person.
CA-MRSA infections were initially deﬁned by a set of criteria
established by the CDC (Buck et al., 2005). These deﬁnitions ex-
cluded infections arising from traditional healthcare-associated
risks such as residence in a long-term care facility, recent hospital-
ization or the need for hemodialysis. The infection was further de-
ﬁned as starting in the community and, for hospitalized patients,
564 A.-C. Uhlemann et al. / Infection, Genetics and Evolution 21 (2014) 563–574isolation of the clinical isolate within 48 h of admission. Alterna-
tively investigators identiﬁed the strains associated with commu-
nity-based outbreaks and infections based on the molecular
characteristics of the isolates. These included the pulsed ﬁeld gel
electrophoresis (PFGE) proﬁle, multilocus sequence type (MLST
or ST) or staphylococcal protein A (spa) type as well as the staph-
ylococcal chromosomal cassette mec (SCCmec) type (see below
for more details). The SCCmec type deﬁnes the mobile element that
carries the gene responsible for methicillin resistance. A ﬁnal dis-
tinction between the community and healthcare-associated (HA)
staphylococci was their antibiotic susceptibility with the health-
care-associated isolates having a broad range of resistance to dif-
ferent antibiotic families while the CA-MRSA isolates, while
resistant to methicillin, were susceptible to many other antibiotics
(David and Daum, 2010; Miller et al., 2007).
Many of the discriminating features that distinguished the com-
munity from the HA strains are no longer valid (David et al., 2008;
Miller et al., 2007). Increasingly, the highly successful community-
based clones have invaded the healthcare setting and are now suc-
cessful nosocomial pathogens. In many medical centers they have
become a common cause of healthcare-associated bacteremias
(Jenkins et al., 2009; Seybold et al., 2006). Along the way they have
also become increasingly antibiotic resistant. As a result, PFGE
types such as USA300 are now commonly found in both settings.
A unique feature of the repeated worldwide MRSA epidemics
has been the discrete number of staphylococcal clones associated
with these events (Chambers and DeLeo, 2009). Rather than a
diversity of strains causing disease as is seen with methicillin-sus-
ceptible S. aureus, the MRSA outbreaks have been limited to a rel-
atively small number of staphylococcal lineages. This is true for
both the strains classically associated with healthcare, as well as
community-based infections. These different staphylococcal lin-
eages have evolved over time, accumulating mutations that alter
gene expression and function, and perhaps most importantly,
acquiring new genetic elements via horizontal gene exchange
(Malachowa and DeLeo, 2010). These new elements have been crit-
ical in altering animal species speciﬁcity, the nature of invasive
infections, and the type antimicrobial resistance associated with
the strains. The capacity to acquire novel elements is essential to
the success of these clones.
The recent emergence of whole genome sequencing as a tech-
nique that can be efﬁciently and inexpensively performed on aTable 1
Characteristics of selected epidemic S. aureus clones
Strain (clonal complex) SCCmec
type
Time period Geographic locations
Phage-type 80/81
(CC30)
NA 1950s–1960s Australia, New Zealan
States, Canada), Europ
Denmark)
EMRSA-16 (CC30/ST36) II 1992–present Europe (especially the
America (United State
Southwest Paciﬁc
Clone (CC30/USA)
IV Australia, New Zealan
the United Kingdom),
America
ST239, Brazilian or
Hungarian clone,
EMRSA-1 (CC8)
III 1980s–present Asia (includes Saudi A
Australia, Europe (incl
Kingdom, Germany), N
States), South America
(e.g., Malaysia, Thailan
USA300 (CC8/ST8) IV Early 2000s–present Primarily North Amer
also present in Europe
NA, not applicable; HA, hospital-associated; CA, community-associated; SSTI, skin and slarge scale has provided a powerful new tool to explore the evolu-
tion of these highly successful clones. Insights have included a bet-
ter understanding of the contribution of selected genes to
virulence, the epidemiology of outbreaks and strain transmission
and an understanding of the molecular changes that facilitate the
spread of these strains from one animal species to another (DeLeo
et al., 2011; Harris et al., 2010; Uhlemann et al., 2012b). In this pa-
per, we review the evolution of three highly successful community
and healthcare-associated lineages, clonal complex 30 (CC30),
ST239, and ST8 (USA300) (Table 1). These unique clones demon-
strate remarkable plasticity in their ability to adapt to environmen-
tal changes. The contribution of the new sequencing methods to
our understanding of the evolution of these clones is also
discussed.2. Evolution of healthcare-associated MRSA: the CC30 lineage
As a ﬁrst step toward understanding the evolution of health-
care-associated S. aureus, it is important to provide a cursory
description of methods used to categorize or type S. aureus.
Phage-typing was among the ﬁrst successful methods used to
understand S. aureus epidemiology and outbreaks (Williams
et al., 1953). The method utilizes the differential susceptibility of
S. aureus clones and isolates to cytolysis by different bacterio-
phages. Although phage typing was an important advance for early
epidemiological studies of S. aureus, it has since given way to more
precise molecular typing methods. MLST (or ST) is a widely used
typing method that indexes variation accumulating slowly over
time, and can thus be used to measure evolution over an extended
period (Enright et al., 2000; Enright and Spratt, 1999). By compar-
ison, PFGE indexes variation that accumulates rapidly and is highly
discriminatory; typing by this method is appropriate for studies of
outbreaks or short-term epidemiological studies (Enright and
Spratt, 1999). The US Centers for Disease Control and Prevention
(CDC) established a national database of PFGE types to monitor
the prevalence of MRSA (McDougal et al., 2003). A third widely
used typing method, known as spa typing, is suitable for analysis
of local or widespread S. aureus outbreaks (Shopsin et al., 1999).
Based on MLST, PFGE, and spa typing, there are multiple health-
care-associated MRSA (HA-MRSA) lineages and clones worldwide
(Chambers and DeLeo, 2009; Grundmann et al., 2010).Characteristics
d, North America (United
e (United Kingdom,
HA and CA infections. Notorious for causing fatal
infections in neonates.
United Kingdom), North
s), South America (Brazil)
HA-MRSA. Leading cause of MRSA infections in
the United Kingdom in the 1990s and early 2000s.
This clone contains inactivating mutations in
genes encoding alpha-hemolysin and accessory
gene regulator subunit C.
d, Samoa, Europe (primarily
Asia, North America, South
CA-MRSA.
rabia, Russia, China, Korea),
udes Portugal, Spain, United
orth America (United
(Brazil), Southeast Asia
d, Singapore)
Pandemic clone. A recombinant strain comprised
of genomic DNA from CC8 and CC30 lineages.
ica & South America; but Epidemic CA-MRSA strain. Most prominent cause
of community bacterial infections in the United
States. Now also a cause of HA-MRSA infection.
oft tissue infections.
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assign the majority of MRSA isolates, including all major MRSA
clones, to ﬁve clonal complexes (CCs) (Enright et al., 2002). Some
MRSA lineages are dispersed globally (for example, STs belonging
to CC30), whereas others appear in speciﬁc geographic locations
(Chambers and DeLeo, 2009; Enright et al., 2002). It should also
be noted that molecular data on MRSA are still incomplete or lack-
ing for many regions of the world. Although current typing meth-
ods are highly useful for tracking S. aureus outbreaks, and they
provide information important for our understanding of pathogen
evolution, they index variation at a relatively small number of
nucleotides. By comparison, whole-genome sequencing ap-
proaches have the ability to provide the full extent of genetic diver-
sity among S. aureus isolates, and this method has become
increasingly employed to better understand the evolution of MRSA.
There is simply no space here to provide a comprehensive re-
view of the evolution of all HA-MRSA lineages. Therefore, we focus
our discussion on selected HA-MRSA lineages for which recent
genome-scale analyses have revealed new insights into the emer-
gence and success of each.2.1. EMRSA-16/ST36 and evolution of the phage-type 80/81 lineage
2.1.1. Phage-type 80/81 S. aureus
Strains that belong to CC30 are among the most prominent
causes of S. aureus human infections. A penicillin-resistant S. aureus
clone known as phage-type 80/81 S. aureus, which based on mod-
ern typing methods is a CC30 clone, was pandemic in the 1950s
and 1960s (Blair and Carr, 1958; Bynoe et al., 1956; Gillespie and
Alder, 1957; Rountree and Freeman, 1955). The pandemic caused
by phage-type 80/81 S. aureus was one of the major bacterial pan-
demics of the 20th century and caused infections—many of them
fatal—in both hospital and community settings (Hassall and Roun-
tree, 1959). Infections manifested initially as pustules, boils, ab-
scess, or carbuncles, which then frequently led to invasive
syndromes such as cellulitis, sepsis, and pneumonia (Blair and Carr,
1958; Hassall and Rountree, 1959). Moreover, the strain was pen-
icillin-resistant, a major problem for treatment. Rountree and Free-
man ﬁrst reported outbreaks in newborns at Royal Prince Alfred
Hospital in Sydney, Australia (Rountree and Freeman, 1955). In
1954, 43 members of the Royal Prince Alfred Hospital staff ac-
quired infections (primarily boils) caused by this strain, and a
number of long-time hospitalized patients suddenly developed
skin lesions from which the same strain was isolated (Rountree
and Freeman, 1955). Rountree and Freeman reported that infec-
tions with phage-type 80/81 S. aureus need not be accompanied
by nasal carriage, albeit carriage in healthcare staff and in new-
borns was noted frequently (Light et al., 1975; Rountree and Beard,
1958; Rountree and Freeman, 1955).
Phage-type 80/81 S. aureus was known for its exceptional viru-
lence and high infectivity and transmissibility (Blair and Carr,
1958; Gillespie and Alder, 1957; Hassall and Rountree, 1959). In-
deed, Gillespie and Alder reported in 1958 that this clone was
the predominant S. aureus phage-type responsible for hospital-ac-
quired infections in the United States (Gillespie and Alder, 1957),
ﬁndings in accordance with data from Canada (Bynoe et al.,
1956). However, by the mid-to-late 1960s, nasal carriage and the
number of infections caused by phage-type 80/81 S. aureus had de-
clined dramatically (Jessen et al., 1969; Light et al., 1975). Jessen
et al. (1969) suggested that the decline of this epidemic clone
might be due to its susceptibility to newly introduced antibiotics
such as methicillin, although there is no conclusive evidence for
this hypothesis. Thus, an explanation for the emergence, spread,
and ultimate decline of the phage-type 80/81 S. aureus ‘‘epidemic
wave’’ remained largely unknown.2.1.2. Epidemic MRSA-16 (EMRSA-16)
Approximately 25 years after the decline of phage-type 80/81 S.
aureus (1991), another CC30 strain—this time an MRSA strain—
emerged as a signiﬁcant cause of infections in hospitals in North-
hamptonshire, England (Cox et al., 1995). This newly emerged
strain, known as EMRSA-16 (later identiﬁed as an ST36 strain),
spread rapidly among hospitals in England and ultimately became
one of the most successful HA-MRSA strains in United Kingdom
(Murchan et al., 2004). Notably, EMRSA-16 and EMRSA-15 (ST22,
not discussed here) isolates accounted for 95% of MRSA bactere-
mias in the United Kingdom during the period of 1998–2000 (John-
son et al., 2001). The ﬁrst reported infections were in elderly
patients with risk factors for infection (e.g., post-surgery) or those
who are seriously ill (Cox et al., 1995). These patients were typi-
cally colonized with EMRSA-16 in the nose, throat, and areas of
broken skin, and the organism caused a range of infections, includ-
ing septicemia, which was often fatal. In addition, most isolates
were resistant to multiple antibiotics, including penicillin, methi-
cillin, erythromycin, and ciproﬂoxacin (Cox et al., 1995; Holden
et al., 2004). Murchan et al. (2004) reported that virtually all EMR-
SA-16 isolates were positive for genes encoding staphylococcal
enterotoxins A, (sea), G (seg), and I (sei), and toxic shock syndrome
toxin-1 (tst).
Phage-typing and PFGE were used routinely to track hospital
outbreaks of EMRSA-16 (Murchan et al., 2004). This strain ulti-
mately became the second most abundant cause of HA-MRSA
infections in the United States, and was named USA200 according
to the PFGE nomenclature developed by the CDC (McDougal et al.,
2003). Consistent with ﬁndings in the United Kingdom, USA200/
EMRSA-16 was a leading cause of persistent bacteremia in the
healthcare setting in the United States (Xiong et al., 2009), and
an abundant colonizer and cause of infection in many other coun-
tries (Montesinos et al., 2006). Thus, EMRSA-16, much like phage-
type 80/81 S. aureus (except for its virtual absence as a cause of
community-associated infections), became a major pandemic
MRSA strain. Although EMRSA-16 remains a cause of healthcare-
associated infections, there has been a clear decline in its abun-
dance—especially in the United Kingdom—since 2003 (Ellington
et al., 2010b). The similarity in the decline of EMRSA-16 and
phage-type 80/81 S. aureus is striking and a number of questions
needed to be addressed. For example, was EMRSA-16 simply a
re-emerged MRSA version of phage-type 80/81 S. aureus? How clo-
sely related were these lineages and why was EMRSA-16 largely
restricted to the healthcare setting, whereas phage-type 80/81 S.
aureus caused infections in both the community and healthcare
settings? Phage-type of EMRSA-16 was distinct from that of
phage-type 80/81 (Cox et al., 1995), suggesting that these strains
were not clones.
2.1.3. Concurrent emergence of the Southwest Paciﬁc clone
There was an additional twist to the evolution of the CC30 line-
age. During the period in which EMRSA-16 was abundant, there
emerged a community-associated MRSA (CA-MRSA) strain known
as the Southwest Paciﬁc (SWP) clone (Adhikari et al., 2002; Vande-
nesch et al., 2003). This strain was later typed as ST30 and was re-
ported initially in Australia, New Zealand, and Western Samoa
(Vandenesch et al., 2003). Notably, the SWP clone contained genes
encoding Panton–Valentine leukocidin (PVL), a leukocyte toxin
also present in phage-type 80/81 S. aureus (but not EMRSA-16)
(Vandenesch et al., 2003). Robinson and colleagues subsequently
reported that the SWP clone and phage-type 80/81 S. aureus were
ST30 and closely related (Robinson et al., 2005). Moreover, this
group proposed that the SWP clone was a direct descendant of
phage-type 80/81 S. aureus (Robinson et al., 2005). Although these
ﬁndings had limited bearing on the evolution of HA-MRSA, the
proposed model for the evolution of the CC30 was intriguing.
Fig. 1. Phylogenetic analyses of selected CC30 strains/isolates. Left panel is a
phylogenetic analysis of CC30 strains (indicated by dots or labeled as EMRSA-16)
based upon analysis of a contiguous 1.4 Mb region of the genome. Right panel is a
phylogenetic analysis of CC30 strains based upon concatenated SNPs in the core
genome. SWP, Southwest Paciﬁc clone; 80/81, phage type 80/81 S. aureus;
Contemporary HA, contemporary hospital CC30 isolates. Adapted from DeLeo
et al. (2011).
566 A.-C. Uhlemann et al. / Infection, Genetics and Evolution 21 (2014) 563–574However, new approaches were needed to better understand the
full extent of similarity or diversity between these strains, and
track their evolution.
2.1.4. A genome-sequence based approach to understanding the
evolution of the CC30 lineage
Holden et al. (2004) reported the complete genome sequence
for an EMRSA-16 clinical isolate named MRSA252. These data were
an important step toward a comprehensive understanding of the
evolution of the CC30 lineage, and provided a framework for future
studies that utilize comparative whole-genome sequencing. One of
the noteworthy observations emerging from the EMRSA-16 gen-
ome sequence was that 6% of the genome was novel compared
to the other genomes published at the time (Holden et al., 2004).
This novel genetic material included two genomic islands, indicat-
ing that mobile DNA is exchanged readily by S. aureus, thereby pro-
viding a means for rapid evolution (Holden et al., 2004). Indeed,
Holden et al. noted that all but one of the antibiotic resistance
determinants of EMRSA-16 reside on mobile genetic elements
(MGEs).
To gain an enhanced understanding of the evolution of the CC30
lineage, DeLeo et al. (2011) used comparative whole genome
sequencing to determine the phylogenetic relationship of phage-
type 80/81 isolates, the SWP clone, and selected contemporary
CC30 hospital isolates with EMRSA-16. Analysis of the core gen-
omes of these isolates segregated the representative isolates into
three sublineages within CC30—phage-type 80/81 S. aureus, SWP
clone, and contemporary healthcare-associated CC30 isolates,
including EMRSA-16 (Fig. 1). More notably, the analyses indicate
that neither EMRSA-16 nor SWP clone are direct descendants of
phage-type 80/81 S. aureus (DeLeo et al., 2011). Rather, the data
indicated there was coincident divergence from a recent common
ancestor. Using a larger set of CC30 isolates for genome sequenc-
ing, McAdam et al. veriﬁed the existence of the three independent
lines of descent for these sublineages (McAdam et al., 2012). These
researchers also identiﬁed a fourth (minor) CC30 sublineage re-
lated to EMRSA-16—isolates reported as being recovered from
community-associated infections—and these are either MSSA iso-
lates or contain SCCmec IV (McAdam et al., 2012). Collectively,
the ﬁndings by DeLeo et al. and McAdam et al. resolve the long-
standing controversy about the evolution of the CC30 lineage. That
is, neither the SWP clone nor EMRSA-16 and related strains are
simply re-emerged, methicillin-resistant versions of the phage-
type 80/81 clone (Fig. 1).
In addition to performing phylogenetic analyses, DeLeo et al.
identiﬁed SNPs or other mutations in EMRSA-16 and related con-
temporary CC30 isolates relative to phage-type 80/81 S. aureus that
likely impact interaction with the human host. For example, the
vast majority of healthcare-associated CC30 isolates contained
identical SNPs in the genes encoding alpha-hemolysin (hla) and
accessory gene regulator C (agrC) (DeLeo et al., 2011). These muta-
tions, which result in a premature stop codon in Hla and a non-
conservative amino acid substitution in AgrC (Gly? Arg), were ab-
sent from phage-type 80/81 S. aureus and the SWP clone. Re-creat-
ing these mutations in a phage-type 80/81 isolate eliminated
production of RNAIII (agrCG55R mutant) and Hla (both mutants)
in vitro, and more importantly, the isogenic mutant strains had re-
duced capacity to cause lethal bacteremia or pneumonia in mouse
infection models (DeLeo et al., 2011). In addition, McAdam et al. re-
ported a nonsense mutation in the gene encoding squalene desat-
urase (crtM) in healthcare-associated CC30 isolates relative to
pandemic phage-type 80/81 S. aureus (McAdam et al., 2012). The
mutation in crtM results in the formation of a pseudogene and
likely disrupts production of staphyloxanthin carotenoid—a pig-
ment that confers resistance to neutrophil oxidants (Liu et al.,
2005). Taken together, these ﬁndings provide strong support tothe idea that nucleotide changes in hla, agrC, and crtM in EMRSA-
16 and related strains reduces virulence capacity, and thereby lar-
gely restricts this sublineage to healthcare settings in which indi-
viduals are sick or have underlying risk factors for infection. This
hypothesis is compatible with the known clinical epidemiology
of EMRSA-16 and related clones (see above).
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strains such as EMRSA-16 have reduced virulence capacity in ani-
mal models seems at variance with the known high abundance of
bloodstream infections caused by these strains (Cox et al., 1995;
Fowler et al., 2007; Johnson et al., 2001). This might in part be a
reﬂection of suboptimal infection control measures, which thereby
lead to an increased reservoir of MRSA carriers and subsequent
infections. However, it is possible that decreased virulence capac-
ity of this sublineage compared with community-associated clones
makes them better suited for long-term colonization and persis-
tence in humans, which in turn, increases the chance of bacteremia
in the context of speciﬁc predisposing conditions. It is also possible
(or perhaps likely) that the ability of S. aureus to attenuate viru-
lence is key to its long-term success as a human commensal organ-
ism. Such a phenomenon might have contributed to the decline of
epidemic S. aureus clones such as phage-type 80/81 S. aureus.
Although progress has been made, more information is needed to
understand the basis for the emergence, success and ultimate de-
cline of EMRSA-16 and related strains.
2.1.5. Regulatory mechanisms balancing methicillin resistance versus
virulence
CC30 strains with comparatively low virulence such as EMRSA-
16 commonly exhibit high minimal inhibitory concentrations
(MICs) toward methicillin, i.e. high levels of methicillin resistance.
In contrast, the recently emerged high-virulence community-asso-
ciated MRSA strains such as USA300 have signiﬁcantly lower MICs.
These ﬁndings suggest that a simultaneous strong production of
determinants of virulence and methicillin resistance comes with
a considerable metabolic burden for the bacteria. In support of this
hypothesis, recent reports indicate that there are regulatory mech-
anisms by which the expression of virulence determinants limits
that of mecA, the penicillin binding protein (PBP) 2a responsible
for methicillin resistance, and vice versa. For example, Collins
et al. (2010) reported that CC30 strains harboring SCCmec type II
have reduced virulence capacity (as measured by their ability to
lyse T cells) and lower relative ﬁtness than their methicillin-sensi-
tive relatives. Rudkin et al. (2012) subsequently showed that the
mecA gene is responsible for this regulatory phenomenon. Expres-
sion of PBP2a leads to cell wall changes that inhibit induction of
the global virulence regulator Agr by the Agr-encoded extracellular
autoinducing peptide, which is a crucial part of the Agr quorum-
sensing circuit controlling virulence factor expression (Ji et al.,
1997). Furthermore, Cheung et al. showed that the Agr system,
which is strongly expressed in CA-MRSA strains and may in part
be responsible for high CA-MRSA virulence (Li et al., 2009), inhibits
expression of mecA in the CA-MRSA strain USA300 (Memmi et al.,
2012). These ﬁndings provide an explanation on the molecular le-
vel for the observation that pronounced virulence and high resis-
tance levels to methicillin appear to be mutually exclusive in
MRSA strains.
2.2. St239
2.2.1. Epidemiology of ST239
Research on MRSA outbreaks and epidemic waves has for the
longest time focused on Europe, North America, and Japan. How-
ever, MRSA infections have become a signiﬁcant problem in coun-
tries such as China, India, and parts of Southeast Asia, where the
fast economic development has been accompanied by better
healthcare and increasing hospitalization rates. China, for example,
reports that within the last 10 years, S. aureus infections in hospi-
tals were caused by MRSA strains in >60% of cases (Xiao et al.,
2011). In Asia, HA-MRSA clones are for the most part quite differ-
ent from those found in the Western industrialized countries.
ST239 is (or has been) the most abundant ST recovered from hos-pital infections in Asia (except Japan) and eastern Australia (Aires
de Sousa et al., 2003; Kim et al., 2011; Ko et al., 2005; Liu et al.,
2009; Nimmo et al., 2008; Soo Ko et al., 2005; Xu et al., 2009). In
addition, many MRSA isolates recovered from hospital patients in
South America, Eastern Europe, and the Middle East belong to
ST239 (Brazilian, Portuguese, Hungarian, and Viennese clones)
(Alp et al., 2009; Amorim et al., 2002; Bartels et al., 2008; Grund-
mann et al., 2010; Havaei et al., 2011; Mayor et al., 2007; Melter
et al., 2003; Vivoni et al., 2006; Wisplinghoff et al., 2005). Given
the high population in the countries where it predominates,
ST239 may represent the most successful MRSA lineage
worldwide.
Recently, ST239 moved into the focus of molecular MRSA re-
search, owing to an outbreak in London that could be attributed
to that ST (Edgeworth et al., 2007). The London outbreak strain
(an ST239 strain named TW20) was primarily associated with vas-
cular access device-related bacteremia, suggesting that TW20 has
increased ability to cause bacteremia. Whole-genome sequencing
of TW20 revealed the presence of several mobile genetic elements,
comprising antibiotic resistance among many other genes with un-
known function (Holden et al., 2010). Notably, comparison of a ser-
ies of global ST239 isolates by whole-genome sequencing indicated
that TW20 originated from Asia, as it was more similar to ST239
isolates from Thailand than those from South America or Europe
(Harris et al., 2010).
2.2.2. The surface protein SasX
The association of TW20 with bacteremia and the fact that the
‘‘Asian clade’’ of ST239 is a primary cause of hospital-associated
MRSA infections in Asia prompted the investigation of molecular
factors potentially underlying the epidemiological success of Asian
ST239 strains. Holden et al. described the presence of a /SPb-like
prophage in TW20 that was not found in other S. aureus strains
and only known in a highly similar form from S. epidermidis
RP62A (Holden et al., 2010). Concluding from their genome com-
parisons, Harris et al. reported that the phage is associated with
the Asian clade of ST239 (Holden et al., 2010). The /SPb-like pro-
phage contains genes potentially conferring aminoglycoside resis-
tance, but only one gene that raised researchers’ interest as
potentially responsible for the increased virulence of the Asian
ST239 strains, namely an LPXTG motif-harboring predicted surface
protein encoded close to the 3’ end of the phage.
Li et al. (2012) investigated the recent epidemiology of MRSA
infections in eastern China with a focus on the TW20 /SPb-like
prophage-encoded surface protein, which they called SasX. They
found that the frequency of sasX-positive clones among invasive
MRSA strains had increased signiﬁcantly within the last 10 years.
Furthermore, the sasX gene, which is apparently always linked to
the /SPb-like prophage, was found in increasing numbers among
other STs, indicating horizontal gene transfer. Potentially explain-
ing the epidemiological success of sasX-containing strains, Li
et al. (2012) described that SasX increases nasal colonization by
enhanced adherence to epithelial cells. Moreover, SasX caused bac-
terial aggregation, which in turn likely caused the observed sasX-
dependent resistance to neutrophil phagocytosis. Finally, presence
of sasX signiﬁcantly increased pathogen survival in skin and lung
infection models.
The mobile genetic element-encoded SasX protein represents
the ﬁrst molecular determinant linked to pathogenic success dur-
ing an MRSA outbreak. It explains at least in part the success of
ST239 in Asia, because the study suggested that many ST239
strains in Asia appear to harbor the sasX gene. However, it should
be noted that the features of the TW20 outbreak in London, namely
the association with bacteremia and the observed decreased rather
than increased colonization capacities compared to other MRSA
strains (Holden et al., 2010), are difﬁcult to interpret based on sasX.
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ST239 is caused by a variety of factors, some of which are still un-
known. These factors may also vary in importance in a speciﬁc geo-
graphical situation, where different subsets of competing MRSA
clones are present.2.2.3. Evolutionary History of ST239
Robinson and Enright ﬁrst reported the remarkable evolution-
ary history of ST239 (Robinson and Enright, 2004). Their study re-
vealed that ST239 is a hybrid of ST8 and ST30, founded by a single
large chromosomal replacement (Robinson and Enright, 2004).
Whole genome sequencing of TW20 further characterized the
likely mechanism of DNA transfer from CC30 into a CC8 strain.
Although TW20 belongs to CC8 based on MLST, and 82% of the
protein coding sequences matched those in CC8 strains, 86% of
the coding sequences matched those in MRSA252, the sequenced
EMRSA-16 (CC30) isolate described above (Holden et al., 2004,
2010). Interestingly, the additional CC30-like genetic material is
present on MGEs, suggesting that a major recombination event
lead to the formation of a chimeric strain containing genetic mate-
rial from CC8 (80%) and CC30 (20%) strains (Holden et al., 2010).
Virtually all ST239 isolates harbor an SCCmec type III element,
which is present in the DNA transferred from CC30, although curi-
ously this SCCmec type has not been reported in CC30 isolates
(Holden et al., 2010). In an effort to better understand the popula-
tion structure of the ST239 lineage, Smyth et al. (2010) used 111
isolates recovered worldwide to identify three major clades and
several minor sublineages or haplotypes of ST239 that are differen-
tiated by point mutations. These authors estimate that the origin of
the most recent common ancestor for these global isolates was
between 1945 and 1961, a time period encompassing the introduc-
tion of penicillin and methicillin. Importantly, the original SCCmec
type III element has apparently been maintained by ST239 and not
reacquired multiple times by MSSA progenitors (Smyth et al.,
2010). These observations suggest that a single clone of ST239
disseminated globally and underwent diversiﬁcation, a ﬁnding at
variance with the explanation for the worldwide abundance of
ST5 MRSA, which arose in speciﬁc geographic locations by the
repeated acquisition of SCCmec by ST5 MSSA strains (Nubel et al.,
2008).3. Community-associated MRSA
In the early 1990s, an increasing number of MRSA infections ac-
quired from the community emerged in patients who did not have
the traditional healthcare risk factors. These infections were ﬁrst
recognized in limited outbreaks from different parts of the world
such as in the indigenous communities of Western Australia and
in several regions of the United States (Udo et al., 1993). The death
of four children from rural Minnesota and North Dakota without
nosocomial exposures marked the formal recognition of this new
entity of S. aureus infections (CDC, 1999). Phenotypic and molecu-
lar characterization of CA-MRSA isolates further demonstrated that
they differed from the major circulating MRSA clones, varied be-
tween different countries and were only resistant to beta-lactam
antibiotics.
CA-MRSA infections most frequently affect the skin and soft tis-
sues, but they have also been linked to severe invasive disease,
such as necrotizing pneumonia and sepsis, often in young and
otherwise healthy individuals. Outbreaks of CA-MRSA have been
associated with several common features including close contact,
poor hygienic conditions, shared equipment/supplies, high risk of
superﬁcial skin abrasions, and lack of access to medical care to
treat infections.While the early stages of the CA-MRSA era were characterized
by a diversity of clones, since then only a small number of predom-
inant clones have become established, such as ST93 in Australia,
ST80 in Europe and ST8 in the United States Here, we will focus
our discussion on ST8-USA300, currently the most widespread
CA-MRSA strain and compare its epidemiology and cardinal geno-
typic characteristics with other prominent CA-MRSA clones.
3.1. CC8
3.1.1. Epidemiology of USA300
By the early 2000s, a single clone named USA300 based on a
newly established PFGE nomenclature (McDougal et al., 2003),
was established as the most predominant clone in the United
States (Tenover and Goering, 2009). Molecular typing further clas-
siﬁed this strain as ST8, most commonly spa type t008 and harbor-
ing SCCmec type IV, genes encoding Panton–Valentine leukocidin
(PVL), and the msr(A) erythromycin resistance genes.
The CDC ﬁrst formally recognized USA300 in an outbreak of CA-
MRSA infections among football players in Pennsylvania in 2000
(CDC, 2003a). Subsequently, this clone was also identiﬁed in an
outbreak investigation of SSTIs in correctional facilities in Missis-
sippi, Georgia, California, and Texas (CDC, 2001, 2003b), as well
as among athletes in Colorado, Indiana and Los Angeles County
(CDC, 2003a). No clear link between any of these outbreaks could
be established. Subsequently, a single PFGE-type, USA300-0114,
was recognized as the predominant strain in the United States
and led to an astronomical increase in MRSA infections. For exam-
ple, by 2005 it was estimated that 90% of all MRSA infections in
San Francisco were community-associated (Liu et al., 2008).
The dominance of USA300 as the primary CA-MRSA cause of
SSTIs was demonstrated in a nationwide study from urban emer-
gency departments in the United States, as USA300 was isolated
from 98% of SSTIs in some parts of the country (Moran et al.,
2006; Talan et al., 2011). USA300 has now become ﬁrmly estab-
lished in Canada. The international spread of USA300 to every con-
tinent except Antarctica is well documented, although it has not
become as dominant in these countries yet (David and Daum,
2010).
Early after its ﬁrst recognition it was already noted that USA300
rapidly contributed to the burden of MRSA infections acquired in
the hospital setting (Liu et al., 2008). In 2004, this clone accounted
for 28% of healthcare-associated bloodstream infections and 20% of
nosocomial infections (Seybold et al., 2006). In parallel to its emer-
gence in the healthcare setting, USA300 has increasingly accumu-
lated resistance to a variety of antibiotics (Coombs et al., 2012;
Talan et al., 2011), which may in part account for its increasing
resilience in the hospital setting. Resistance has mainly been ac-
quired through plasmids conferring resistance to clindamycin
(ermA and ermC), tetracycline (tetK and tetM) (Tenover et al.,
2006) and mupirocin (mupA) (Diep et al., 2008a). In addition, resis-
tance to ﬂuoroquinolones, conferred by chromosomal mutations,
continues to be on the rise (Moran et al., 2006; Talan et al.,
2011). Several USA300 isolates have also developed reduced sus-
ceptibility to vancomycin, and in some cases, to daptomycin
(Graber et al., 2007; Hafer et al., 2012; Hageman et al., 2008), in
addition to occasional resistance to gentamicin and trimetho-
prim–sulfamethoxazole. The prospect of increasing multi-drug
resistance in USA300 strains with high virulence potential is a
source of great concern.
Virulence alone is unlikely to account for the extraordinary
dominance of USA300 infections. Although increased nasal coloni-
zation with USA300 was notably absent from the initial outbreak
investigations of already antibiotic-treated patients, the ﬁrst evi-
dence for an increase in USA300 colonization on a population
level was documented by the National Health and Nutrition
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2006). This survey of nasal swabs collected from 5000 non-insti-
tutionalized people over 4-year period reported a statistically sig-
niﬁcant increase in USA300 during the 2001–2004 study period,
and speciﬁcally in USA300-0114—the epidemic clone (Tenover
et al., 2006). Although the percent of USA300 nasal colonization
in non-institutionalized individuals increased during this time per-
iod, the overall level was relatively low (prevalence of MRSA nasal
colonization was 1.5%, of which only 19.7% were USA300 or
USA400) (Gorwitz et al., 2008), and perhaps could not account
for the high overall burden of USA300 in the community. Direct
skin-to-skin contact with infected or colonized individuals (in the
absence of nasal colonization), or with contaminated objects, was
suspected as the route of transmission (Kazakova et al., 2005). In-
deed, it is now known that some MRSA and USA300 in particular
appear to have an enhanced propensity to colonize extra nasal
body sites, such as inguinal and perirectal skin regions (Miko
et al., 2012; Peters et al., 2010; Senn et al., 2012). This enhanced
ability to colonize additional body sites is an intriguing vehicle
for the widespread transmission of USA300 in communities. More-
over, USA300 is also more frequently recovered from environmen-
tal surfaces in community households, which has been directly
linked to transmission between household members (Knox et al.,
2012; Uhlemann et al., 2011). This enhanced prevalence on fomites
might reﬂect the increased burden of USA300 colonization of mul-
tiple body sites in individuals or rather an increased capacity of
USA300 to survive on inert surfaces.
3.1.2. USA300 genomics and evolution
The complete genome sequence of a USA300 isolate, FPR3757,
was reported by Diep et al. (2006); a second genome was published
shortly thereafter by Highlander et al. (2007). By comparing the
USA300 genome to ten other S. aureus genomes, a substantial num-
ber of novel genes were identiﬁed. These genes mainly cluster
within ﬁve regions of the genome, including a novel pathogenicity
island (SaPI5) encoding two enterotoxins Seq and Sek (Diep et al.,
2006). Most remarkably, the sequence revealed the horizontal
acquisition of a novel MGE, the arginine catabolic mobile genetic
element (ACME), containing gene clusters for the arginine deami-
nase pathway and an oligopeptide permease system. This element
was absent from other S. aureus strains but present at high preva-
lence in the skin commensal S. epidermidis (Diep et al., 2006).
A number of studies have since addressed the genomic evolu-
tion of USA300 (Kennedy et al., 2008; Tewhey et al., 2012; Uhle-
mann et al., 2012a). Kennedy et al. ﬁrst compared the genomes
of ten geographically diverse USA300 isolates and noted that all
but two isolates differed by only a discrete number of SNPs, sug-
gesting a recent divergence from a common ancestor (Kennedy
et al., 2008). Importantly, the ﬁndings provide strong support to
the idea that there has been clonal emergence of USA300 and sub-
sequent spread throughout the United States, rather evolutionary
convergence and the independent emergence of similar organisms.
It is also noteworthy that two of these clonal isolates exhibited sig-
niﬁcantly decreased mortality in a mouse sepsis model, supporting
the idea that minimal changes in the core genome can signiﬁcantly
impact S. aureus virulence.
To gain understanding of the adaptation of USA300 in commu-
nities, Uhlemann et al. (2012a) sequenced eight longitudinally
sampled USA300 isolates collected over 15 months from three
community households. The greatest genetic heterogeneity oc-
curred between isolates from different households and within
one heavily colonized household, although phylogenetic analysis
suggested that all but one isolate likely arose from a recent com-
mon ancestor. Sequencing of persisting USA300 isolates identiﬁed
a small number novel non-synonymous SNPs, deletions, and small
genome rearrangements, preferentially in genes involved in themajor functional categories aspects of adhesion, cell wall biosyn-
thesis, virulence, and carbohydrate metabolism. The observed
small genome rearrangements may provide an intriguing mecha-
nism for rapid genome diversiﬁcation and host niche adaptation.
A remarkable genetic similarity of USA300 isolates was also
noted by Tewhey et al. (2012), who compared 18 USA300 isolates
from SSTIs and 18 from severe infections collected over nearly
5 years in a deﬁned geographic region (Tewhey et al., 2012).
Non-synonymous mutations were more frequently accumulated
in virulence genes of SSTI isolates, ﬁndings that may explain in part
the ability of strains to cause mild versus severe disease.
Although progress has been made, many open questions remain
regarding the evolution of USA300 as it has adapted to both com-
munity and healthcare settings.
3.1.3. Putative virulence factors of USA300
While many of the initial studies tried to link the enhanced vir-
ulence phenotype of USA300 to MGEs, in particular to prophage-
encoded PVL, several lines of research in experimental animalmod-
els suggest that there is little or no contribution of MGEs to USA300
virulence, with the exception of necrotizing pneumonia and per-
haps during the early stages of skin infections (DeLeo et al., 2010;
Diep et al., 2008b, 2010; Kobayashi et al., 2011; Li et al., 2010;
Lipinska et al., 2011; Montgomery et al., 2009; Voyich et al.,
2006). Studies of human infections largely support these observa-
tions, except that PVL does not contribute to a worse outcome for
patients with complicated SSTIs (Bae et al., 2009). In contrast, mod-
ulated expression of core-genome encoded a-toxin (Hla), phenol-
soluble modulin-alpha peptides (PSMa) and accessory gene regula-
tor (Agr) have a dramatic inﬂuence on virulence in several animal
models of infection (Bubeck Wardenburg et al., 2007; Kobayashi
et al., 2011; Li et al., 2010; Wang et al., 2007). PSMs are small
cytolytic peptides that serve many different functions in S. aureus
pathogenesis. They contribute to the structure as well as the dis-
semination of bioﬁlms (Periasamy et al., 2012) and propagate
inﬂammation (Li et al., 2010; Wang et al., 2007). A variant, PSM-
mec, is encoded on select SCCmec elements and when present in
high amounts relative to other PSMs, contributes signiﬁcantly to
S. aureus virulence (Queck et al., 2008). Furthermore, a previously
unrecognized core-genome encoded toxin, staphylococcal entero-
toxin-like toxin X (SEIX), contributes signiﬁcantly to lethality in a
rabbit necrotizing pneumonia model (Wilson et al., 2011).
To further elucidate the origin of USA300, Li et al. (2009) com-
pared several major MRSA isolates in a combination of virulence
and genotyping assays. These studies indicated that USA300 and
USA500 have a high capacity for virulence and an enhanced ability
to evade the host immune response. The noted enhanced virulence
capacity was due to an increased expression of core genome-en-
coded virulence determinants, such as PSMs and a-toxin (Li
et al., 2009). Based on sequence comparisons of seven housekeep-
ing genes and seven surface protein encoding genes, this study also
established USA500 as the progenitor of USA300, which ultimately
acquired ACME, a SaPI that encodes enterotoxin K (sek) and entero-
toxin Q (seq), and the prophage encoding lukSF-PV.
The fact that the virulence phenotype of USA300 was already
established in its USA500 progenitor also argues that the acquisi-
tion of MGEs has played a limited role in the evolution of
USA300 virulence, and suggests that these elements have a differ-
ent role in S. aureus biology. In light of the incomparably higher
spread of USA300 compared to USA500, it has been speculated that
these MGEs are more important for transmission of USA300 rather
than contributing to virulence.
3.1.4. ACME—a putative ﬁtness factor of USA300
ACME has been the premier candidate as a MGE ﬁtness
factor, based on its putative involvement in pH homeostasis.
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USA300, especially on skin, has remained unknown. ACME
encompasses a 30.9 kb genomic region, encoding 33 genes,
and is thought to have been acquired from coagulase negative
staphylococci (Diep et al., 2006). ACME was ﬁrst implicated as
a virulence factor in a rabbit bacteremia model (Diep et al.,
2008b), although a subsequent study found no evidence that
ACME directly contributes to the virulence of USA300 using a
rat model of necrotizing pneumonia and a mouse model of skin
infection (Montgomery et al., 2009). These ﬁndings appear at
variance, but differences in the animal species (rabbit versus
rat and mouse) or infection models (bacteremia versus pneumo-
nia or skin infection) used could account for the reported differ-
ences in the contribution of ACME to virulence.
Linking in the observation that S. aureus is uniquely hypersensi-
tive to polyamines, which are encountered in high concentrations
during infection and in inﬂamed skin, Joshi and colleagues demon-
strated that USA300 exhibited complete resistance to polyamines
(Joshi et al., 2011). This polyamine-resistant phenotype depended
on the presence of a spermine/spermidine acetyl-transferase
(speG) encoded within the ACME island. The abrogation of the host
polyamine enabled a DspeG mutant to persist in infected wounds.
The polyamine resistance of USA300 was also shown to provide a
major ﬁtness advantage during SSTIs but not in sepsis (Thurlow
et al., 2013). However, speG needs to act in conjunction with other
gene clusters within ACME. It was shown that the constitutive
ACME-encoded arginine-deiminase system (Arc) converts arginine
to ornithine and ammonia, which enables survival in an acidic
environment comparable to the human skin. In parallel, this
ACME-Arc system drives the excessive production of host poly-
amines, compounds uniquely toxic to S. aureus, necessitating its
protection by speG (Thurlow et al., 2013).
To date, ACME has only infrequently been encountered in other
S. aureus lineages and has not been ascribed to any other successful
CA-MRSA clone. While initially all USA300 isolates were believed
to carry ACME, more recent studies indicate that between 9% and
15% of USA300 isolates do not harbor this element (Montgomery
et al., 2008; Uhlemann et al., 2011). It is currently unclear if these
ACME-negative isolates represent a distinct sublineage or if their
potential increase indicates that this element is not as stably main-
tained in USA300.
3.1.5. Comparison of USA300 with other major CA-MRSA clones
Despite the number of available genome sequences of CA-
MRSA strains, no clear consensus exists regarding key features
that enabled their collective emergence and success. A number
of studies have compared virulence of select CA-MRSA (and HA-
MRSA) strains in animal models of infection (e.g., Li et al., 2009,
2010; Voyich et al., 2005). Li et al. (2010) found that the most
virulent strains in a rabbit abscess model consisted of USA300,
USA500 and ST80, whereas USA400, an early dominant CA-
MRSA in the United States, caused smaller abscesses by com-
parison. A study by Chua et al. (2011) reported that ST93 was
the most virulent strain among those compared (including
USA300, USA400, and ST239) in wax moth larvae and mouse
skin infection models. Therefore, the virulence observed in ani-
mal models cannot fully explain the prominent distribution or
success of certain CA-MRSA lineages. As another example, the
highly virulent ST80 strain is one of the most frequent CA-
MRSA strains in Europe and is occasionally encountered in Aus-
tralia and North Africa, but it has caused very limited disease
compared to USA300 or ST93 in their respective geographic re-
gions. Like many CA-MRSA strains, ST80 usually harbors PVL
and carries a SCCmec-type IV cassette. Recently, Stegger et al.
(2012) reported the genome of a representative ST80 isolate
from Denmark. This isolate contained a novel SCCmec-type IVcassette with an integrated partial plasmid, as well as three
integrated pro-phages, encoding PVL and immunomodulatory
genes, sak and scn, but no unique identifying features were
reported.
The ST93 Queensland MRSA clone has emerged over the past
decade in Australia, resulting in an increase in CA-MRSA infections
(from 6.6% to 11.5% nationwide). In 2010, this strain constituted
41% of all CA-MRSA infections in Australia, 28% of all MRSA infec-
tions, and 4.9% of all S. aureus community-onset infections (SAP10,
2010). Infections with ST93-MRSA also predominantly manifest as
SSTIs, but an enhanced clinical virulence as evidenced by reports of
severe invasive infection—such as necrotizing pneumonia, deep-
seated abscess, osteomyelitis, septic arthritis and septicemia—has
been suggested (Coombs et al., 2009; Risson et al., 2007). There
are isolated reports of ST93 infections in New Zealand and the
UK, but many of these cases could be epidemiologically linked to
Australia (Ellington et al., 2010a).
By MLST analysis ST93 represents a singleton and is distinct
from other S. aureus clones, but also harbors SCCmec IV [2B] and
PVL. Based on its genome sequence, ST93, like USA300, contains
a-hemolysin, PVL and PSM-a (Chua et al., 2010) gain, no overt no-
vel virulence determinant has been identiﬁed in ST93 that could
easily explain its high virulence capacity, suggesting the contribu-
tion of altered gene expression or subtle genetic alterations in the
core genome. Furthermore, it is tempting to speculate that, while
ST93 is highly virulent, the lack of an obvious ﬁtness factor, such
as the ACME-arcA-speG system in USA300, might account for its
relatively limited geographic distribution.
Lastly, the complete genome sequence of an ST59 CA-MRSA iso-
late, a lineage predominant in Taiwan, was reported recently
(Huang et al., 2012a, 2012b). Since the original identiﬁcation of
ST59, these isolates have frequently been associated with multi-
drug resistance. Compared to the USA300 strain FPR3757 and the
USA4000 strain MW2, most of the open reading frames in the
ST59 strain M013 were highly conserved (Huang et al. 2012a).
However, genomic islands SaPI5 and mSa3 as well as prophages
/Sa3usa and /Sa3 are absent in M013 (Huang et al., 2012a,
2012b). In addition, the majority of the ORFs in the pathogenic-
ity-related genomic island mSab are deleted in the corresponding
region of the M013 genome. ST59 also harbors PVL, but the genes
encoding the toxin appear to have distinct sequence composition.
A comparative genome sequence analysis of multi-drug resistant
ST59 isolates identiﬁed truncated hsdM and hsdS genes on mSab,
and these genes encode part of the restriction-modiﬁcation system
components (Huang et al., 2012a, 2012b). This defect may have
contributed to the acquisition of IS1216V and MMESPM1, which
are enterococcal DNA elements that confer multi-drug resistance
(Hung et al. 2012b).
Taken together, despite a series of genome-scale and genome
sequence analyses of diverse CA-MRSA strains, no single unique
genetic locus has been identiﬁed that accounts for the success of
these strains. While PVL is disproportionally present in many CA-
MRSA lineages, its absence does not appear to diminish the viru-
lence capacity of S. aureus. Perhaps it is not as much the acquisition
of novel virulence factors, but rather a paucity of inactivating
mutations in genes such as hla, agrC or crtM (as discussed above
for the CC30 lineage) that enables CA-MRSA strains to maintain a
high virulence phenotype. This model infers that as successful S.
aureus clones are increasingly exposed to triggers such as the anti-
biotic rich nosocomial environment, they will eventually accumu-
late inactivating mutations that reduce their capacity to cause
severe infections, and this phenomenon thereby promotes survival
of S. aureus as a commensal organism. Alternatively, an enhanced
ability of successful CA-MRSA strains to up-regulate virulence fac-
tors or evade the innate immune response could contribute to their
unique success as pathogens.
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S. aureus is perhaps most widely known as a human pathogen
and for its ability to acquire resistance to antibiotics. However, it
is equally a commensal organism that asymptomatically colonizes
humans and other mammals. It could be argued that the existence
as a commensal microbe is better suited for long-term ﬁtness and
survival (as opposed to life as a pathogen). From that viewpoint,
the emergence or re-emergence S. aureus/MRSA strains that cause
widespread and sometimes fatal infections is somewhat puzzling.
One explanation is that host susceptibility, as with sick or immune
comprised individuals, plays a major role in the emergence of new
strains. That is, strains that normally colonize humans asymptom-
atically have the ability to cause opportunistic infections in a more
susceptible (e.g., sick) host. The ongoing emergence of antibiotic
resistant strains is readily explained by selective pressure in the
healthcare setting, and thus the combination of susceptible hosts
and antibiotic use likely favor emergence of new MRSA strains.
On the other hand, there is no clear explanation for the emergence
and success of speciﬁc MRSA clones such as EMRSA-16. For exam-
ple, why do such strains predominate in speciﬁc geographic loca-
tions and then often decline rapidly to make way for another
unrelated clone? One possibility is that this phenomenon involves
a polygenetic trait and/or the agr locus. Shopsin et al. (Shopsin
et al., 2010) have shown that inactivating mutations in agr provide
a short-term adaptive survival mechanism in the infected host, but
they are deleterious for the long-term transmission of strains.
These observations appear compatible with the ﬁndings of DeLeo
et al. (2011) and McAdam et al. (2012) as discussed above. In addi-
tion, Holden et al. (2013) and Knight et al. (2012) suggested that
the recent replacement of EMRSA-16 with EMRSA-15 as the dom-
inant HA-MRSA strain in the United Kingdom involved accumula-
tion of mutations associated with resistance to ﬂuoroquinolones,
and increased ﬁtness as assessed by growth rate in vitro. The basis
for the increased ﬁtness of EMRSA-15 (CC22) is unknown, but
Knight et al. propose that the smaller SCCmec type IV element of
EMRSA-15 has a reduced ﬁtness cost compared with the larger
SCCmec type II element present in EMRSA-16 strains.
An explanation for the emergence of CA-MRSA also remains a
mystery. The overall burden of antibiotics and widespread use of
antibiotics—in and out of healthcare settings—could have contrib-
uted, but there is no conclusive evidence to support this notion or
explain why CA-MRSA strains have been largely restricted to a se-
lect few lineages. It may be that these strains have arisen by rare
stochastic events, or alternatively, they may be more susceptible
to integration of speciﬁc genetic elements, such as SCCmec type
IV or ACME (for USA300). In any case, more work is needed to
understand the emergence and success of CA-MRSA. These ques-
tions are now being addressed using genome-scale approaches,
which include expression microarrays and genome sequencing.
Such data are an important step toward a comprehensive under-
standing of S. aureus epidemic waves and the evolution of MRSA
in hospitals and the community.
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